Dual-Inducer Gene Switch for Low-Leak Biologics Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inducible expression systems for biologics production in mammalian cells suffer from leakiness and modest efficacy, making it difficult to generate stable cell lines for cytotoxic products.
Innovation Solution
A dual coumermycin/cumate gene-switch system is developed, combining a CymR repressor regulated by a constitutive promoter and λR-GyrB under a cumate-inducible promoter, with transcription control by a coumermycin-inducible promoter, allowing tight regulation of gene expression through two inducers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single inducible expression system (e.g., tetracycline or cumate gene-switch) is used, then the system is simple to implement, but it exhibits leakiness and modest efficacy in regulating gene expression
Solution Approach 1:
The patent divides the gene regulation function into two separate systems: a cumate-inducible promoter for initial transcriptional activation and a coumermycin-responsive element for additional regulation. This segmentation allows each system to perform a specific regulatory function, with the cumate system handling induction and the coumermycin system providing tight control, thereby reducing leakiness while maintaining manageable complexity through functional division
Solution Approach 2:
The patent merges two different inducible expression systems (cumate gene-switch and coumermycin gene-switch) into a hybrid expression cassette. The cumate-inducible promoter drives transcription of a message containing both the gene of interest and the coumermycin-responsive element. This combining approach integrates the advantages of both systems: the ease of cumate induction with the tight regulation of coumermycin response, achieving both effective induction and reduced leakiness
2Productivity
If constitutive synthesis of cytotoxic biologic components is allowed, then the cell line can produce product continuously, but the cells cannot grow properly and become unstable
Solution Approach 1:
The patent implements dynamic control of gene expression through an inducible system that transitions between inactive and active states. The expression cassette remains silent during cell growth and isolation phases, then activates upon addition of the cumate inducer. This dynamic switching allows the cell line to maintain stability during growth while enabling continuous production when needed, resolving the contradiction between cellular stability and productive output
Solution Approach 2:
The patent extracts the toxic gene expression function from the cellular machinery by placing it under the control of an external inducer system. The gene of interest is separated from constitutive expression and extracted into a regulated cassette that only expresses when deliberately activated. This extraction allows the cell line to remain stable and healthy during growth, with production capability that can be activated on demand without compromising cellular stability
3Stability of the object's composition
If an inducible expression system is used to produce cytotoxic biologics, then cell growth is maintained, but the system shows leakiness and modest efficacy in activating gene expression
Solution Approach 1:
The patent incorporates a coumermycin-responsive element within the message that is transcribed upon cumate induction, but the actual translation and functional activation of the gene product is delayed until coumermycin is added. This preliminary action allows the cell to prepare the transcriptional machinery and maintain stability during growth, while the actual productive expression is postponed to when both inducers are present, thereby improving activation efficacy
Solution Approach 2:
The patent uses the coumermycin-responsive element as an intermediary between the cumate-induced transcription and the final gene expression. The message contains both the gene of interest and the coumermycin-responsive element, which acts as a mediator that must be activated by coumermycin to allow full expression. This intermediary mechanism enhances the reliability of gene activation by requiring two sequential steps, preventing leakiness while maintaining cell stability
Data Source
AI summary
The disclosure pertains to tightly regulated inducible expression systems useful for the inducible production of one or more RNAs or proteins of interest, including the production of biologics such as recombinant proteins, vaccines, or viral vectors. Also provided are cell lines and kits useful for the production of said RNAs or proteins, as well as methods for making said cell lines and methods for inducing production of said RNAs or proteins.